Work

FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis

Year: 2018

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2018-eular.5711

Authors: C. Aranow, M. Dall'Era, M. Byron, L. Ding, D. Smilek, B. Diamond, D. Wofsy

Institutions: Feinstein Institute for Medical Research, University of California, San Francisco, Rho (United States), National Institute of Allergy and Infectious Diseases, Immune Tolerance Network

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: GlaxoSmithKline, Sanofi, Celgene, Genentech, Erasmus+, National Institute of Allergy and Infectious Diseases

OpenAlex ID: W2883375285

Cites:

Cited by: 19

Related to: 10